about
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin huma...
Read More
5.54
0.20
(3.75%)
6.8M
XNAS Volume
High vol.+gain this week
XNAS 05 Sep, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Mannkind Corp is on 09 Sep 2025 for the purpose of H.C. Wainwright 27th Annual Global Investment Conference
See details
Not Eligible
Expensive Valuation
Technically Neutral
Mannkind Corp Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..